Loading...

Biotinylated Recombinant SARS-CoV-2 B.1.351 Spike Protein S1 (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
Coronavirus spike Protein, S1, Spike Protein, South Africa variant,beta variant
Ave. Rating
Submit a Review
Product Citations
publications
SARS-CoV-2-_Spike-Protein-S1_BIOTIN-RECOM_1_111522
Biotinylated recombinant SARS-CoV-2 B.1.351 Spike Protein S1 binds to immobilized recombinant human ACE2-Fc (Cat. No. 793202) at 1 μg/mL in a dose-dependent manner. The ED50 for this effect is 15 - 90 ng/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
  • SARS-CoV-2-_Spike-Protein-S1_BIOTIN-RECOM_1_111522
    Biotinylated recombinant SARS-CoV-2 B.1.351 Spike Protein S1 binds to immobilized recombinant human ACE2-Fc (Cat. No. 793202) at 1 μg/mL in a dose-dependent manner. The ED50 for this effect is 15 - 90 ng/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
  • SARS-CoV-2-_Spike-Protein-S1_BIOTIN-RECOM-2_111522
    Stability Testing for Recombinant SARS-CoV-2 B.1.351 Spike Protein S1. Recombinant SARS-CoV-2 B.1.351 Spike Protein S1 was aliquoted in PBS at 0.2 mg/mL. One aliquot was frozen and thawed four times (4x Freeze/Thaw), and compared to a control kept at 4°C (control). The samples were tested by their ability to bind to immobilized recombinant human ACE2-Fc chimera at 1 μg/mL in a dose dependent-manner. The ED50 for this effect is 15 - 90 ng/mL.
Cat # Size Price Save
798104 25 µg ¥62,690
798106 100 µg ¥105,080
Description

SARS-CoV-2 is a respiratory virus which causes coronavirus disease 2019 (COVID-19). The coronavirus spike (S) glycoprotein is a class I viral fusion protein on the outer envelope of the virion that plays a critical role in viral infection by recognizing host cell receptors and mediating fusion of the viral and cellular membranes. The S glycoprotein is synthesized as a precursor protein consisting of ~1,300 amino acids that is then cleaved into an amino (N)-terminal S1 subunit (~700 amino acids) and a carboxyl (C)-terminal S2 subunit (~600 amino acids). Three S1/S2 heterodimers assemble to form a trimer spike protruding from the viral envelope. The S1 subunit contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. Triggered by receptor binding, proteolytic processing and/or acidic pH in the cellular compartments, the class I viral fusion protein undergoes a transition from a metastable pre-fusion state to a stable post-fusion state during infection, in which the receptor-binding subunit is cleaved, and the fusion subunit undergoes large-scale conformational rearrangements to expose the hydrophobic fusion peptide, induce the formation of a six-helix bundle, and bring the viral and cellular membranes close for fusion. The trimeric SARS coronavirus (SARS-CoV-2) S glycoprotein consisting of three S1-S2 heterodimers binds the cellular receptor angiotensin-converting enzyme 2 (ACE2) and mediates fusion of the viral and cellular membranes through a pre- to post-fusion conformation transition. SARS-CoV-2 B.1.351, South Africa variant, has multiple changes in the spike protein and the mutations in the in the RBD result in stronger ACE2 binding.

Product Details
Technical data sheet

Product Details

Source
SARS-CoV-2 B.1.351 Spike Protein S1, amino acid Val16-Arg685 (Accession # QHD43416.1), with (D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G) and a C-terminal 8His and Avi-tag was expressed in CHO cells. SARS-CoV-2 B.1.351 Spike Protein S1 Avi-tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass
The 704 amino acid recombinant protein has a predicted molecular mass of approximately 78.4 kD. The DTT-reduced and non-reduced proteins migrate to approximately 100 - 110 kD and 90 -100 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Val.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in PBS, pH 7.2
Endotoxin Level
Less than 0.1 EU per µg protein as determined by the LAL method.
Concentration
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C to 8°C up to 2 weeks, at -20°C up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Biotinylated recombinant SARS-CoV-2 B.1.351 Spike Protein S1 binds to immobilized recombinant human ACE2-Fc (Cat. No. 793202) at 1 μg/mL in a dose-dependent manner. The ED50 for this effect is 15 - 90 ng/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Monomer
Distribution

SARS-CoV-2

Function
Attaches the virion to the cell membrane by interacting with host receptor (ACE2) initiating the infection
Interaction
Ciliated cells in nasal mucosa and bronchus
Ligand/Receptor
ACE2
Bioactivity
Measured by its ability to bind to recombinant human ACE2-Fc
Cell Type
Endothelial cells, Macrophages, NK cells, T cells
Biology Area
Adaptive Immunity, Immunology, Innate Immunity
Antigen References
  1. Lu R, et al. 2020. Lancet. 395:565-574. 
  2. Li F. 2016. Annu Rev Virol. 3:237-261.
  3. Belouzard S, et al. 2012. Viruses. 4:1011-33.
  4. Song W, et al. 2018. PLoS Pathog. 14:e1007236.
  5. Li F, et al. 2020. Nature. 581:221-224.
  6. Radvak P, et al. 2021. Nat Commun. 12:6559. 
Gene ID
43740568 View all products for this Gene ID
UniProt
View information about S1 on UniProt.org
Go To Top Version: 1    Revision Date: 11/15/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account